CLDXCelldex Therapeutics, Inc.

CLDX Stock Price, Valuation & Chart | Celldex Therapeutics, Inc.

Compare

$39.480+0.24 (+0.61%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology CLDX intrinsic value CLDX calculated fair value vs price

Overview Financials Dividends Ratios

CLDX Historical price chart

CLDX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization2.63B

PE Ratio-9.27

EPS-4.26

Trading Volume475.88K

Today's High/Low40.46/39.01

Dividend Yield0.00

52 Week High/Low45.14/21.77

Shares Outstanding66.54M

CLDX Financial Statement

CLDX Analyst ratings

CLDX Analysis & performance metrics

CLDX Company profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its…

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that…

CLDX Management team

Name

Position

Joseph P. Schlessinger Ph.D.

Co-Founder & Member of Scientific Advisory Board

Sarah Cavanaugh

Senior Vice President of Corporate Affairs & Administration

Margo Heath-Chiozzi M.D.

Senior Vice President of Regulatory Affairs

Anthony S. Marucci M.B.A.CEO

Founder, President, Chief Executive Officer & Director

Richard M. Wright Ph.D.

Chief Commercial Officer & Senior Vice President

Sam Martin CPACFO

Senior Vice President, Chief Financial Officer, Secretary & Treasurer

Ronald A. Pepin Ph.D.

Chief Business Officer & Senior Vice President

Tibor Keler Ph.D.

Founder, Chief Scientific Officer & Executive Vice President

Name

Position

Joseph P. Schlessinger Ph.D.

Co-Founder & Member of Scientific Advisory Board

Sarah Cavanaugh

Senior Vice President of Corporate Affairs & Administration

Margo Heath-Chiozzi M.D.

Senior Vice President of Regulatory Affairs

Anthony S. Marucci M.B.A.CEO

Founder, President, Chief Executive Officer & Director

Richard M. Wright Ph.D.

Chief Commercial Officer & Senior Vice President

Sam Martin CPACFO

Senior Vice President, Chief Financial Officer, Secretary & Treasurer

Ronald A. Pepin Ph.D.

Chief Business Officer & Senior Vice President

Tibor Keler Ph.D.

Founder, Chief Scientific Officer & Executive Vice President

Management Team

Joseph P. Schlessinger Ph.D.

Co-Founder & Member of Scientific Advisory Board

Sarah Cavanaugh

Senior Vice President of Corporate Affairs & Administration

Margo Heath-Chiozzi M.D.

Senior Vice President of Regulatory Affairs

Anthony S. Marucci M.B.A.CEO

Founder, President, Chief Executive Officer & Director

Richard M. Wright Ph.D.

Chief Commercial Officer & Senior Vice President

Sam Martin CPACFO

Senior Vice President, Chief Financial Officer, Secretary & Treasurer

Ronald A. Pepin Ph.D.

Chief Business Officer & Senior Vice President

Tibor Keler Ph.D.

Founder, Chief Scientific Officer & Executive Vice President

Management

Joseph P. Schlessinger Ph.D.

Co-Founder & Member of Scientific Advisory Board

Sarah Cavanaugh

Senior Vice President of Corporate Affairs & Administration

Margo Heath-Chiozzi M.D.

Senior Vice President of Regulatory Affairs

Anthony S. Marucci M.B.A.CEO

Founder, President, Chief Executive Officer & Director

Richard M. Wright Ph.D.

Chief Commercial Officer & Senior Vice President

Sam Martin CPACFO

Senior Vice President, Chief Financial Officer, Secretary & Treasurer

Ronald A. Pepin Ph.D.

Chief Business Officer & Senior Vice President

Tibor Keler Ph.D.

Founder, Chief Scientific Officer & Executive Vice President

Total 8 executives

CLDX Frequently asked questions

What is Celldex Therapeutics, Inc. (CLDX) Stock Price?

Current stock price of Celldex Therapeutics, Inc. (CLDX) stock is $39.480. The stock price is +0.61% higher in the session. The intraday range can be seen from this page. Volume of Celldex Therapeutics, Inc. (CLDX) stock is 475.88K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Celldex Therapeutics, Inc. (CLDX) stock price going up or down today?

The stock price of Celldex Therapeutics, Inc. (CLDX) can change with earnings, company news, and overall market sentiment. Celldex Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Celldex Therapeutics, Inc. stock expensive at its current price?

Whether Celldex Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for CLDX on this page is -9.27. EPS on this page is -4.26. Compare those figures with peers and growth expectations before deciding if the current Celldex Therapeutics, Inc. price is justified.

How has the stock price of Celldex Therapeutics, Inc. (CLDX) performed historically?

Historical performance for Celldex Therapeutics, Inc. (CLDX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how CLDX reacted to past earnings and market events.

Should I buy Celldex Therapeutics, Inc. (CLDX) stock, at this price?

Buying Celldex Therapeutics, Inc. (CLDX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.